Print
Share
Request More Information
Structural Heart | Tissue Heart Valves | Aortic Supra-Annular Stented Valves

Biocor™ Supra Stented Tissue Valve

Product Highlights

  • Provides a larger stent-to-annulus ratio than Biocor aortic valve
  • Delivers proven 20-year durability results 1,2
  • Three separate porcine leaflets are matched to optimize leaflet coaptation and reduce stress
  • The outflow edge is covered with a pericardial shield, providing a tissue-to-tissue interface to reduce the risk of abrasion
  • FlexFit™ stent reduces leaflet stress, adapts easily to annulus to enhance knot positioning, and returns stent posts to original shape after deflection
  • Low-profile design provides optimal coronary ostia clearance
  • Short 2 x 10-second rinse time
Biocor<sup>™</sup> Supra Stented Tissue Valve


Ordering Information

Contents: Aortic Supra-Annular Stented Tissue Valve (1 unit per box)

Reorder Number Valve Size (mm) Tissue Annulus Diameter (mm) Internal Diameter (mm) Aortic Protrusion (mm) Total Height (mm)
BSP100-19 19 19 19 11 14
BSP100-21 21 21 21 11 15
BSP100-23 23 23 23 13 16
BSP100-25 25 25 25 13 17
BSP100-27 27 27 27 14 19

1. Myken PS, Bech-Hansen O. A 20-year experience of 1712 patients with the Biocor porcine bioprosthesis. J Thorac and Cardiovasc Surg. 2009;137(1):76-81.

2. Eichinger WB, Hettich IM, Ruzicka DJ, et al. Twenty-year experience with St. Jude Medical Biocor bioprosthesis in the aortic position. Ann Thorac Surg. 2008;86(4):1204-1210.

Rx Only

St. Jude Medical Stented Tissue Valves are indicated for use as a replacement for malfunctioning native or prosthetic aortic and/or mitral valves. Adverse events potentially associated with the use of bioprosthetic heart valves include: angina, cardiac arrhythmia, endocarditis, heart failure, hemolysis, hemolytic anemia, hemorrhage (anticoagulant/antiplatelet-related), leak (transvalvular or paravalvular), myocardial infarction, nonstructural dysfunction (e.g., pannus, suture, inappropriate sizing, or other), prosthesis regurgitation, stroke, structural deterioration (e.g., calcification, leaflet tear, or other), thromboembolism and valve thrombosis. It is possible that these complications could lead to reoperation, explantation, permanent disability or death. Long-term anticoagulation and/or anti-platelet therapy should be considered in patients with dilated left atrium, a history of thrombotic events or a cardiac rhythm of atrial fibrillation or flutter. Please see the Instructions for Use (IFU) for a full description of indications, contraindications, side effects, precautions, warnings and Instructions for Use.

Unless otherwise noted, ™ indicates that the name is a trademark of, or licensed to, St. Jude Medical or one of its subsidiaries. ST. JUDE MEDICAL and the
nine-squares symbol are trademarks and service marks of St. Jude Medical, Inc. and its related companies. ©2014 St. Jude Medical, Inc. All rights reserved.

100033292 – May 2012

Customer Support: 855-478-5833

Last Updated: April 19, 2013